Raised CSF phosho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications

C A Goodall, M W Head, D Everington, J W Ironside, R S G Knight, A J E Green

Objective: To investigate whether phosphorylated tau protein (tau-pT181) is increased in variant Creutzfeldt–Jakob disease (vCJD) and if the tau-pT181/tau protein ratio is useful for distinguishing between patients with and without CJD.

Methods: CSF tau protein and tau-pT181 were measured in 50 patients with sporadic CJD (sCJD), 51 patients with vCJD, 46 sCJD controls, and 37 vCJD controls, using Innovaest hTau and Innovest P-Thr181, Innogenetics.

Results: Concentrations of CSF tau protein were increased in sCJD (5120 ± 367 pg/ml in controls, p<0.001) and vCJD (952 ± 106 pg/ml, p<0.001); tau-pT181 was also raised in sCJD (61 ± 35 pg/ml in controls, p=0.002) and vCJD (114 ± 33 pg/ml, p<0.001). Median concentrations of tau-pT181 were higher in vCJD than in sCJD (p<0.001). The tau-pT181/tau protein ratio was lower than in controls in both sCJD (12 ± 128 (p<0.001)) and vCJD (119 ± 279 (p<0.001)). Mean tau-pT181/tau protein ratio was 10-fold higher in vCJD than in sCJD. Raised CSF tau protein had the highest efficiency for distinguishing sCJD and vCJD from controls.

Conclusions: CSF tau-pT181 concentrations are raised in vCJD and are higher than in sCJD. Measurement of CSF tau-pT181/tau protein ratio does not improve the diagnostic efficiency of CSF tau protein alone for either vCJD or sCJD. The higher concentration of CSF tau-pT181 found in vCJD suggests that unexplained pathogenic factors influence the phosphorylation of tau protein in vCJD patients.

Methods: CSF samples from patients referred to the National CJD Surveillance Unit (NCJDSU) were analysed for tau protein and tau-pT181. The methodology of the NCJDSU has been described elsewhere. All patients or their medical notes, or both, were examined by the NCJDSU. Consecutive patients were selected according to the volume of CSF available for analysis. CSF was analysed from the following patients: 51 patients with neuropathologically proven or clinically probable vCJD, 37 vCJD control patients, 50 patients with neuropathologically proven or clinically probable sCJD, and 46 sCJD control patients. Thirty two patients had neuropathologically confirmed vCJD (21 male, 11 female; age range 16 to 54 years (mean 30) at notification) and 19 patients had probable vCJD (eight male, 11 female; age range 18 to 50 years (mean 29) at notification). Thirty seven patients had neuropathologically confirmed sCJD (17 male, 20 female; age range 50 to 81 years (mean 63) at notification) and 13 had probable sCJD (six male, seven female; age range 44 to 77 years (mean 66) at notification).

The sCJD and vCJD control groups consisted of patients who were initially suspected of having sCJD and vCJD, respectively, and in whom an alternative diagnosis was made. Of the 37 vCJD control patients (16 male, 21 female; age range 14 to 79 years (mean 31) at notification), neuropathological examination was carried out on seven cases. The diagnoses in six of these were paraneoplastic syndrome (2), Huntington’s chorea (1), multiple sclerosis (1), subacute sclerosing panencephalitis (1), and viral encephalopathy (1). In the remaining case there was no definite neuropathologically confirmed diagnosis on brain biopsy, but no evidence of vCJD. The diagnosis of vCJD was excluded in the remaining 30 vCJD control patients for reasons that included complete or partial recovery (10), or an alternative diagnosis made on clinical grounds, or investigations suggestive of an alternative diagnosis (20). The diagnoses in these 20 cases were psychiatric disorders (7), non-CJD dementia of an unknown cause (5), encephalitis (4), Alzheimer’s disease (1), cerebrovascular disease (1), epilepsy (1), and mitochondrial cytopathy (1).

Of the 46 sCJD control patients (18 male, 28 female; age range 41 to 84 (mean 68) at notification), 20 had a postmortem neuropathological examination. The diagnoses in 17 of these cases were: Alzheimer’s disease (6), Lewy body dementia (2), cerebrovascular disease (2), angiotropic lymphoma (1), carcinomatosis of leptomeninges (1), cerebral vasculitis (1), ischaemic encephalopathy (1), multifocal demyelination (1), multifocal lymphoma (1), and viral demyelination (1), multifocal encephalitis (1), and viral encephalitis (1).

Abbreviations: tau-pT181, tau protein phosphorylated at threonine-181; CJD, Creutzfeldt–Jakob disease; sCJD, sporadic CJD; vCJD, variant CJD; NCJDSU, The National CJD Surveillance Unit
encephalitis (1). In the remaining three cases, there was no definite neuropathologically confirmed diagnosis on brain biopsy, but no evidence of sCJD. The diagnosis of sCJD was excluded in the final 26 patients for reasons that include partial recovery (5), or an alternative diagnosis made on clinical grounds, or investigations suggestive of an alternative diagnosis (21). The diagnoses in these 21 cases were: Lewy body dementia (3), non-CJD dementia of an unknown cause (3), frontal lobe dementia (2), Alzheimer’s disease (2), Hashimoto’s encephalitis (2), paraneoplastic syndrome (2), central pontine myelinolysis (1), cerebrovascular ischaemia (1), granulomatous disease (1), Huntington’s disease (1), paraneoplastic encephalitis (1), vascular dementia (1), and vasculitis (1).

**RESULTS**

CSF concentrations of tau protein, tau-pT181, and the tau-pT181/tau protein ratio for both sCJD and vCJD and the relevant control groups are shown in fig 1. The diagnostic value of each of these markers is shown in table 1.

Efficiency was defined as the number of true positive and true negative values expressed as a percentage of the total number of patients investigated. Cut off values for tau-pT181 and the tau-pT181/tau protein ratio were calculated using receiver operator curves; the cut off value used for tau protein was that previously described.⁴

The mean concentration of CSF tau-pT181 was significantly raised in vCJD patients compared with vCJD control patients (114 ± 33 pg/ml, p < 0.001) and sCJD patients (114 ± 61 pg/ml, p < 0.001). The mean concentration of tau-pT181 was raised in sCJD patients compared with sCJD controls (61 ± 35 pg/ml, p = 0.002). There was no evidence of an effect of age, sex, or disease duration on the tau-pT181 protein concentration in either sCJD or vCJD.

The mean concentration of CSF tau protein was significantly raised in vCJD and sCJD when compared with the appropriate control groups (952 ± 106 pg/ml, p < 0.001; and 5120 ± 367 pg/ml, p < 0.001, respectively). CSF tau protein had the greatest efficiency for discriminating between both vCJD and sCJD from their respective control patients (table 1). There was a strong correlation between tau protein and tau-pT181 protein in vCJD patients and vCJD controls (Spearman’s test, p < 0.001), no evidence of a correlation in sCJD patients (p = 0.3), and slight evidence of a correlation in sCJD controls (p = 0.049).

The tau-pT181/tau protein ratios for vCJD and sCJD were significantly lower than in the appropriate control groups (114 ± 279, p < 0.001; 12 ± 128, p < 0.001, respectively), but this ratio did not improve the diagnostic efficiency of CSF tau protein alone (table 1).

**DISCUSSION**

Patients with vCJD and sCJD had significantly raised concentrations of tau protein and tau-pT181 compared with control patients. Interestingly the concentration of CSF tau-pT181 was higher in vCJD patients than in sCJD or either group of control patients. As there was no correlation between tau-pT181 concentration and age or disease duration in either vCJD or sCJD, the difference in mean concentration between these two forms of CJD is unlikely to be explained by the younger age or the longer clinical course in vCJD patients.

The fact that the mean concentration of tau-pT181 is higher in vCJD than in sCJD, in contrast to tau protein levels where the reverse is true, suggests that the factors governing the release or metabolism of tau protein and tau-pT181 are different in these two forms of CJD. It is thought that tau protein is released into the CSF as a result of neuronal damage or death and that the magnitude of the concentrations reflects the extent and rate of this process. As sCJD has...
a more rapid clinical course than vCJD this would explain the higher mean concentrations of CSF tau protein in sCJD than in vCJD. The higher mean concentrations of CSF tau-pT181 in vCJD than in sCJD or in the control patients suggests that there are factors as yet unexplained that influence the phosphorylation of tau protein in vCJD patients. CSF tau-pT181 concentrations are increased in Alzheimer’s disease, a condition associated with neurofibrillary tangles (NFTs), but there is no neuropathological evidence that vCJD patients have NFTs or any other tau inclusion bodies. At present, it is unclear whether this increase in tau-pT181 results from increased phosphorylation of tau protein or from a reduction or resistance to de-phosphorylation.

The mean tau-pT181/tau protein ratio in vCJD was significantly lower than in the relevant control group but was not as efficient as the CSF tau protein alone in discriminating between these two groups of patients. Interestingly the tau-pT181/tau protein ratio is higher in vCJD than in sCJD and reflects the differences in magnitude of the two proteins in the two forms of CJD.

Conclusions
CSF tau-pT181 is the only surrogate marker investigated so far that is significantly raised in vCJD when compared with sCJD and controls. Despite this, measurement of CSF tau-pT181 or calculation of the tau-pT181/tau protein ratio does not improve the diagnostic accuracy of tau protein alone. Whether raised CSF tau-pT181 levels may be of diagnostic value in distinguishing between vCJD and sCJD in a clinical setting will require further investigation. Interestingly the observation that vCJD patients have higher concentrations of CSF tau-pT181 than patients with sCJD suggests that the pathogenic factors governing the phosphorylation of tau protein in these two conditions are different.

ACKNOWLEDGEMENTS
This study was funded by a grant from the Department of Health, UK (grant No 007/0075). The National CJD Surveillance Unit is funded by the Department of Health and the Scottish Home Office Department of Health.

### Table 1

<table>
<thead>
<tr>
<th>SCJD:</th>
<th>Tau protein ≥1300 pg/ml</th>
<th>Tau-pT181 ≥50 pg/ml</th>
<th>Tau-pT181/tau protein ratio ≤60</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity (%)</td>
<td>84</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Specificity (%)</td>
<td>91</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Efficiency (%)</td>
<td>88</td>
<td>60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VCJD:</th>
<th>Tau protein ≥400 pg/ml</th>
<th>Tau-pT181 ≥70 pg/ml</th>
<th>Tau-pT181/tau protein ratio ≤200</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity (%)</td>
<td>90</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>Specificity (%)</td>
<td>89</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Efficiency (%)</td>
<td>90</td>
<td>85</td>
</tr>
</tbody>
</table>

---

**Authors’ affiliations**
C A Goodall, M W Head, D Everington, J W Ironside, R S G Knight, A J E Green, The National Creutzfeldt-Jakob Disease Surveillance Unit, Western General Hospital, Crewe Road, Edinburgh, UK

Competing interests: none declared

Correspondence to: Dr Alison Green, The National CJD Surveillance Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK; Alison.Green@ed.ac.uk

Received 16 February 2005
In revised form 4 April 2005
Accepted 10 April 2005

**REFERENCES**


www.jnnp.com